



Our World-Class Research Institute Is Looking for Scientific Leaders

Since its inception, The Methodist Hospital Research Institute has challenged the notion of "by-the-book" medical research. Led by Mauro Ferrari, Ph.D., President and CEO, the Research Institute is a 440,000-square-foot research enterprise for The Methodist Hospital System in Houston, TX, and is affiliated with the Weill Cornell Medical College in New York City. Methodist is transforming medicine with emerging techniques, and a staff that is developing real treatments and cures every day. Our laboratories are equipped with advanced technology and facilities that include a cyclotron, pre-clinical and clinical imaging, flow cytometry and microscopy, small and large animal vivariums; and a GMP facility for nanoparticles, contrast agents, vaccines, and therapeutic molecules. Our facility is a vertically integrated state-of-the-art laboratory for translational and clinical research where translational researchers and physician scientists bring ideas to clinical applications.

We are now searching for research professionals to serve in a variety of capacities.

Program leaders in the fields of:

- Neurodegenerative Diseases and Repair of the Nervous System (Methodist Neurological Institute)
- Cardiovascular Science (Methodist DeBakey Heart & Vascular Center)
- Cancer Biology (Methodist Cancer Center)

Senior scientists in the fields of:

- Diabetes and Metabolic Disorders (Methodist Center for Diabetes, Obesity and Lipids)
- Transplant Immunology (Methodist Transplant Center)

Candidates should be nationally and internationally recognized leaders with an outstanding track record of scientific discovery, funded research, programmatic leadership and academic mentorship. We will provide you with a position in the epicenter of medical research. You'll discover an excellent research environment, state-of-the-art equipment, and the chance to follow your research from discovery to clinical application in a single facility. Applicants should submit a Statement of Scientific Interest, a Curriculum Vitae, and the names of three references to: Tong Sun, Director of Central Research Administration, The Methodist Hospital Research Institute, 6670 Bertner St., M.S. R2-216, Houston, TX 77030, or email facultyapplications@tmhs.org (please specify applying field in the subject line of email). Our success as an organization is due to the diversity of our team. We are an equal opportunity employer.

www.tmhri.org

www.MethodistHealth.com

Metholist The Methodist Hospital Research Institute^{*}

Houston, TX

LEADING MEDICINE[®]

The Methodist Hospital System is the official health care provider of the Houston Texans, Houston Astros, Houston Dynamo, Rice Athletics, Houston Ballet, Houston Grand Opera and Houston Symphony.



Medizinsche Fakultät Heidelberg

Am Pharmakologischen Institut der Universität Heidelberg (Komm. Geschäftsf. Direktorin: Prof. Dr. R. Kuner) ist ab sofort eine

W₃-Professur für Pharmazeutische Pharmakologie

neu zu besetzen.

life

Die Stelleninhaberin/Der Stelleninhaber hat das Fach in Forschung und Lehre zu vertreten. Von den Kandidaten/-innen werden eine Habilitätion oder eine gleichwertige Qualifikation, hervorragende wissenschaftliche Leistungen auf dem Gebiet der Experimentellen Pharmakologie sowie die Fähigkeit zur selbstständigen Leitung einer international kompetitiven Forschergruppe erwartet. Das Forschungsgebiet des/der Kandidaten/-in kann alle Bereiche der Pharmakologie umfassen, wobei eine Angliederung an die Forschungsschwerpunkte der Medizinischen Fakultät und eine Beteiligung an bestehenden oder ge-planten Sonderforschungsbereichen der Universität Heidelberg angestrebt wird. Mit der Übernahme der Professur ist die Verantwortung für die Lehre im Fach Pharmakologie des Studienganges Pharmazie verbunden. Darüber hinaus wird eine Beteiligung an der Lehre der Pharmakologie für Studenten der Biowissenschaften erwartet.

Auf die weiteren in § 47 und § 48, Abs. 3, Satz 4, des baden-württembergischen Landeshochschulgesetzes genannten Einstellungsvoraussetzungen wird hingewiesen.

Die Universität Heidelberg strebt eine Erhöhung des Anteils der Frauen im wissen-schaftlichen Personal an und fordert qualifizierte Frauen nachdrücklich auf, sich zu bewerben. Schwerbehinderte werden bei gleicher Qualifikation bevorzugt eingestellt.

Bitte richten Sie Ihre Bewerbung innerhalb von **vier Wochen** nach Erscheinen der Anzeige an **Prof. Dr. C. R. Bartram, Dekan der Medizinischen Fakultät Heidelberg, Im Neuenheimer Feld 672, 69120 Heidelberg.** Ihre Bewerbungsunterlagen sollen den Kriterien entsprechen, welche Sie unter http://med.uni-hd.de/berufungen_ hinweise_bewerber.html einsehen können. W211903B

offline ONE nformatior find others public make DOST naturejobs 1005

New Naturejobs blog goes live

How can you make more informed career or hiring decisions?

- Follow the blog on naturejobs.com to keep up-to-date with the latest scientific employment news from around the world.

What do you think about the news stories affecting scientific careers?

- Start sharing your opinions today on the Naturejobs blog.

www.naturejobs.com

E‰onMobil

Taking on the world's toughest energy challenges. $\!\!\!\!^{\scriptscriptstyle M}$

Member of Technical Staff – Algae Biofuels

ExxonMobil Research and Engineering has an immediate opening for a Member of the Technical Staff in its Corporate Strategic Research laboratory located in Annandale, NJ.

Candidates are sought to fill a bioengineer position in the Algae Biofuels program, which is part of ExxonMobil's strategic alliance with Synthetic Genomics, Inc. This program is a new long-term investment focused on biofuel production from photosynthetic algae. If successful, these next generation biofuels could augment the world's transportation fuel supply and assist in reducing greenhouse gas emissions in the decades to come.

The successful candidate will be part of a team working on the design, operation and testing of reactor systems to grow and harvest algae. Responsibilities will include implementing, testing and modifying prototype photo bioreactors, algae harvesting equipment and oil recovery systems. This individual will also interact with design teams and contractors. A PhD in chemical or mechanical engineering or related field is required. Requirements include reactor engineering expertise, bioreactor design experience, as well as experience in experimental design. A background in photosynthesis is a plus.

ExxonMobil's Corporate Strategic Research (CSR) laboratory is a dynamic and exciting place to work. CSR is located in scenic western New Jersey, about an hour west of New York City and 45 minutes northwest of Princeton. Within CSR, active research programs exist in all areas of the company's business and include the traditional fields of chemical engineering, materials science, chemistry, physics, geoscience and mechanical engineering. Interdisciplinary research is the norm, and close ties are maintained with the academic and national laboratory communities through publication and presentation of results.

ExxonMobil offers an excellent working environment and a competitive compensation and benefits package. Please submit your cover letter and resume to our website at **www.exxonmobil.com/ex** and apply to Bioengineer.

ExxonMobil is an Equal Opportunity Employer

E‰onMobil

Taking on the world's toughest energy challenges.^*

Member of Technical Staff – Algae Biofuels

ExxonMobil Research and Engineering has an immediate opening for a Member of the Technical Staff in its Corporate Strategic Research laboratory located in Annandale, NJ.

Candidates are sought to fill a phycology position in the Algae Biofuels program, which is part of ExxonMobil's strategic alliance with Synthetic Genomics, Inc. This program is a new long-term investment focused on biofuel production from photosynthetic algae. If successful, these next generation biofuels could augment the world's transportation fuel supply and assist in reducing greenhouse gas emissions in the decades to come.

The successful candidate will be part of a team working on all areas related to algae strain selection, improvement and cultivation at lab, pilot and demonstration scale. Responsibilities will include defining and executing an experimental program aimed at maximizing the production of oils from microalgae to manufacture a full range of transportation fuels (gasoline, jet or diesel) which meet the same specifications as today's products. The successful candidate will have a strong background in phycology, algae aquaculture, algae ecology and biology. Additionally, a background in photosynthesis and photo-physics is a plus. Ideally, the successful candidate would also have practical experience in large scale algae production and an understanding of biology and engineering fundamentals for carrying out largescale aquaculture. A PhD in phycology or biology or related field is required. The candidate must be capable of independently developing high-level and broadbased research programs, have excellent analytical skills, demonstrate strong leadership skills, and have outstanding communication skills.

ExxonMobil's Corporate Strategic Research (CSR) laboratory is a dynamic and exciting place to work. CSR is located in scenic western New Jersey, about an hour west of New York City and 45 minutes northwest of Princeton. Within CSR, active research programs exist in all areas of the company's business and include the traditional fields of chemical engineering, materials science, chemistry, physics, geoscience and mechanical engineering. Interdisciplinary research is the norm, and close ties are maintained with the academic and national laboratory communities through publication and presentation of results.


ExxonMobil offers an excellent working environment and a competitive compensation and benefits package. Please submit your cover letter and resume to our website at **www.exxonmobil.com/ex** and apply to Phycologist.

ExxonMobil is an Equal Opportunity Employer

Young Investigators Awards in São Paulo, Brazil

FAPESP, the São Paulo Research Foundation, is one of the main research funding agencies in Brazil. With a 2010 budget of US\$ 450 million, it supports more than 11,000 scholarships and 8,000 research awards. FAPESP's Young Investigators Awards envisage creating new research groups led by highly promising early-career scientists in any field of knowledge and from any country. Selected candidates receive competitive fellowships and sizable research funds. Candidates are encouraged to develop their projects with higher education and research institutions from the State of São Paulo, Brazil. Highlighted research areas are: biodiversity, bioenergy, climate change, neurosciences, cancer, urban studies, materials science, optics and photonics, urban studies and violence. Proposals in other fields will be considered and all will be selected through a peer-reviewing process.

For guidance and further information: yi@fapesp.br Additional information: http://www.fapesp.br/en/materia/4479



University of ULSTER

Norbrook

The Norbrook Chair in Pharmaceutical Science

The University has recently established a Department of Pharmacy and Pharmaceutical Sciences and is committed to its development as an area of excellence. Significant progress has already been achieved in this regard. The Department of Pharmacy and Pharmaceutical Sciences is part of the School of Biomedical Sciences and will make a significant contribution to the Biomedical Sciences Research Institute. Biomedical Sciences research at Ulster has a national and international reputation achieving top scores in the last three UK-wide Research Assessment Exercises.

Following the receipt of a generous gift from Norbrook Laboratories Ltd the University wishes to appoint an outstanding individual to the founding Norbrook Chair in Pharmaceutical Science. The appointee to this prestigious position will provide research leadership, establish internationally competitive agenda-setting research at Ulster and extend the University's focused research portfolio in pharmaceutical formulation, novel drug delivery, and pharmaceutical science.

The successful applicant will have an outstanding academic or industrial track record, with a strong focus on fundamental and translational research in the area of drug formulation and pharmaceutical science.

The appointee will be offered a permanent professorship within the Department of Pharmacy and Pharmaceutical Sciences and will hold the title of the Norbrook Chair in Pharmaceutical Science for an initial period of five years. The Norbrook Chair includes a significant research support package which will be negotiated with the appointee.

An attractive reward package, including a competitive starting salary, access to a pension scheme and financial assistance with relocation expenses is also available.

The post will be based at the Coleraine campus and is available from 1 September 2011 or as soon as possible thereafter. The closing date for receipt of completed applications is **3 June 2011**

We prefer to issue and receive applications via our on-line recruitment website at **www.ulster.ac.uk/jobs**

Hard copy applications can be obtained by telephoning **028 7012 4072.** The reference number for this post is 1185278

The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities. Appointment will be made on merit.





15th June 2011 Royal College of Physicians London

EPIC 8 European Partnering and Investment Conference

www.epicbiotech.com

EPIC will once again be showcasing the best of European biotechs in a one day format. 60 European and UK biotech companies will be presenting, looking for partners, investment or services. The sessions will be based on therapeutic areas including Oncology, CNS, Immunology, Vaccines, Infection, Regen Med/Tissue Eng and Platform & Diagnostics.

Oslo Cancer Cluster will be showcasing some of their top oncology companies. Partnering will take place throughout the day to make those initial meetings with 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors. Industry keynotes will set the tone for the day and the post conference drinks reception will be held in the College gardens.

Contact: Director Simon Tarpey

simontarpey@epicbiotech.com

/////0664/8

U211980E



naturejobs





August 30 – September 3, 2011 Boston, MA, USA Marriott Copley and Westin Copley

"Integrating Technology and Medicine For a Healthier Tomorrow"

SPEAKER ANNOUNCEMENT

Dean Kamen

Corporation

DEKA Research and Development

John A. Parrish, M.D.

Subra Suresh, Ph.D.

National Science Foundation

Kamil Ugurbil. Ph.D.

University of Minnesota

& Innovative Technology

Center for Integration of Medicine

J. Craig Venter, Ph.D. J. Craig Venter Institute

David J. Balaban, Ph.D. Research & Development Informatics, Amgen Inc.

Mara G. Aspinall, M.B.A. On-Q-ity, Inc.

Angela Belcher Ph.D. Massachusetts Institute of Technology

Emilio Bizzi, M.D., Ph.D. Massachusetts Institute of Technology

Roni Zeiger, M.D. Google Inc

Conference Themes:

- Biomedical Signal Processing
- Biomedical Imaging & Image Processing
- Bioinstrumentation: Sensors, Micro, Nano and Wearable Technologies
- Bioinformatics, Computational Biology; Systems Biology, Modeling Methodologies
- Cardiovascular & Respiratory Systems Engineering
- Neural Engineering, Neuromuscular Systems & Rehabilitation Engineering
- Molecular and Cellular Biomechanics, Tissue Engineering, Biomaterials
- Bio-Robotics , Surgical Planning and Biomechanics
- Therapeutic & Diagnostic Systems , Devices and Technologies, Clinical Engineering
- Healthcare Information Systems , Telemedicine
- Technology Commercialization, Education, Industry and Society

Conference Chair: Paolo Bonato, Harvard Medical School Conference Co-Chair: Colin Brenan, CS2 Technologies LLC Program Chair: Andrew Laine, Columbia University Program Co-Chair: Metin Akay, University of Houston Webmaster: Ming Jack Po, Columbia University Program Coordinator: Pamela Reynolds, Spaulding Rehabilitation Hospital

Visit us on the web! http://embc2011.embs.org/

NW211079EL

| NATUREJOBS | 21 APRIL 2011